CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma
Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we inv...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Wiley
2023-03-01
|
| Colecção: | Cancer Medicine |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1002/cam4.5512 |
| _version_ | 1827974996311408640 |
|---|---|
| author | Junya Yamaguchi Fumiharu Ohka Chalise Lushun Kazuya Motomura Kosuke Aoki Kazuhito Takeuchi Yuichi Nagata Satoshi Ito Nobuhiko Mizutani Masasuke Ohno Noriyuki Suzaki Syuntaro Takasu Yukio Seki Takahisa Kano Kenichi Wakabayashi Hirofumi Oyama Shingo Kurahashi Kuniaki Tanahashi Masaki Hirano Hiroyuki Shimizu Yotaro Kitano Sachi Maeda Shintaro Yamazaki Toshihiko Wakabayashi Yutaka Kondo Atsushi Natsume Ryuta Saito |
| author_facet | Junya Yamaguchi Fumiharu Ohka Chalise Lushun Kazuya Motomura Kosuke Aoki Kazuhito Takeuchi Yuichi Nagata Satoshi Ito Nobuhiko Mizutani Masasuke Ohno Noriyuki Suzaki Syuntaro Takasu Yukio Seki Takahisa Kano Kenichi Wakabayashi Hirofumi Oyama Shingo Kurahashi Kuniaki Tanahashi Masaki Hirano Hiroyuki Shimizu Yotaro Kitano Sachi Maeda Shintaro Yamazaki Toshihiko Wakabayashi Yutaka Kondo Atsushi Natsume Ryuta Saito |
| author_sort | Junya Yamaguchi |
| collection | DOAJ |
| description | Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigated the correlation of MYD88 L265P and CD79B Y196 mutations, which are the most frequently found molecular alterations in PCNSL, with prognosis of patients with PCNSL treated with R‐MPV. Methods We investigated the long‐term clinical course and status of MYD88 and CD79B genes in 85 patients with PCNSL treated with R‐MPV or HD‐MTX treatment, and the correlation of these genetic mutations with prognosis. Results R‐MPV achieved an excellent tumor control rate (61.6% and 69.9% of 5‐year progression‐free and overall survival rates, respectively). While MYD88 L265P mutation had no significant effect on survival, patients with CD79B Y196 mutations exhibited prolonged survival (p < 0.05). However, the association of CD79B Y196 mutation with a better prognosis was not observed in the HD‐MTX cohort, which indicated that CD79B Y196 mutation was a predictive marker for a favorable response to R‐MPV. Furthermore, we established an all‐in‐one rapid genotyping system for these genetic mutations. Conclusions In conclusion, CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in PCNSL. The rapid identification of MYD88 L265P and CD79B Y196 mutations can be helpful not only for the accurate molecular diagnosis of PCNSL but also for the prediction of response to R‐MPV. |
| first_indexed | 2024-04-09T20:02:55Z |
| format | Article |
| id | doaj.art-9032b57cfdb94eec8ed1c32a18c58b14 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T20:02:55Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-9032b57cfdb94eec8ed1c32a18c58b142023-04-02T20:55:00ZengWileyCancer Medicine2045-76342023-03-011267116712610.1002/cam4.5512CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphomaJunya Yamaguchi0Fumiharu Ohka1Chalise Lushun2Kazuya Motomura3Kosuke Aoki4Kazuhito Takeuchi5Yuichi Nagata6Satoshi Ito7Nobuhiko Mizutani8Masasuke Ohno9Noriyuki Suzaki10Syuntaro Takasu11Yukio Seki12Takahisa Kano13Kenichi Wakabayashi14Hirofumi Oyama15Shingo Kurahashi16Kuniaki Tanahashi17Masaki Hirano18Hiroyuki Shimizu19Yotaro Kitano20Sachi Maeda21Shintaro Yamazaki22Toshihiko Wakabayashi23Yutaka Kondo24Atsushi Natsume25Ryuta Saito26Department of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya Central Hospital Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Konan Kosei Hospital Konan JapanDepartment of Neurosurgery Konan Kosei Hospital Konan JapanDepartment of Neurosurgery Aichi Cancer Center Hospital Nagoya JapanDepartment of Neurosurgery Nagoya Medical Center Nagoya JapanDepartment of Neurosurgery Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya JapanDepartment of Neurosurgery Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya JapanDepartment of Neurosurgery Anjo Kosei Hospital Anjo JapanDepartment of Neurosurgery Toyohashi Municipal Hospital Toyohashi JapanDepartment of Neurosurgery Toyohashi Municipal Hospital Toyohashi JapanDepartment of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDivision of Cancer Biology Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Neurosurgery Nagoya University Graduate School of Medicine Nagoya JapanAbstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigated the correlation of MYD88 L265P and CD79B Y196 mutations, which are the most frequently found molecular alterations in PCNSL, with prognosis of patients with PCNSL treated with R‐MPV. Methods We investigated the long‐term clinical course and status of MYD88 and CD79B genes in 85 patients with PCNSL treated with R‐MPV or HD‐MTX treatment, and the correlation of these genetic mutations with prognosis. Results R‐MPV achieved an excellent tumor control rate (61.6% and 69.9% of 5‐year progression‐free and overall survival rates, respectively). While MYD88 L265P mutation had no significant effect on survival, patients with CD79B Y196 mutations exhibited prolonged survival (p < 0.05). However, the association of CD79B Y196 mutation with a better prognosis was not observed in the HD‐MTX cohort, which indicated that CD79B Y196 mutation was a predictive marker for a favorable response to R‐MPV. Furthermore, we established an all‐in‐one rapid genotyping system for these genetic mutations. Conclusions In conclusion, CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in PCNSL. The rapid identification of MYD88 L265P and CD79B Y196 mutations can be helpful not only for the accurate molecular diagnosis of PCNSL but also for the prediction of response to R‐MPV.https://doi.org/10.1002/cam4.5512CD79BMYD88primary central nervous system lymphomarapid molecular diagnosisR‐MPV |
| spellingShingle | Junya Yamaguchi Fumiharu Ohka Chalise Lushun Kazuya Motomura Kosuke Aoki Kazuhito Takeuchi Yuichi Nagata Satoshi Ito Nobuhiko Mizutani Masasuke Ohno Noriyuki Suzaki Syuntaro Takasu Yukio Seki Takahisa Kano Kenichi Wakabayashi Hirofumi Oyama Shingo Kurahashi Kuniaki Tanahashi Masaki Hirano Hiroyuki Shimizu Yotaro Kitano Sachi Maeda Shintaro Yamazaki Toshihiko Wakabayashi Yutaka Kondo Atsushi Natsume Ryuta Saito CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma Cancer Medicine CD79B MYD88 primary central nervous system lymphoma rapid molecular diagnosis R‐MPV |
| title | CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma |
| title_full | CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma |
| title_fullStr | CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma |
| title_full_unstemmed | CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma |
| title_short | CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma |
| title_sort | cd79b y196 mutation is a potent predictive marker for favorable response to r mpv in primary central nervous system lymphoma |
| topic | CD79B MYD88 primary central nervous system lymphoma rapid molecular diagnosis R‐MPV |
| url | https://doi.org/10.1002/cam4.5512 |
| work_keys_str_mv | AT junyayamaguchi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT fumiharuohka cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT chaliselushun cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT kazuyamotomura cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT kosukeaoki cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT kazuhitotakeuchi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT yuichinagata cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT satoshiito cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT nobuhikomizutani cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT masasukeohno cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT noriyukisuzaki cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT syuntarotakasu cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT yukioseki cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT takahisakano cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT kenichiwakabayashi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT hirofumioyama cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT shingokurahashi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT kuniakitanahashi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT masakihirano cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT hiroyukishimizu cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT yotarokitano cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT sachimaeda cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT shintaroyamazaki cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT toshihikowakabayashi cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT yutakakondo cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT atsushinatsume cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma AT ryutasaito cd79by196mutationisapotentpredictivemarkerforfavorableresponsetormpvinprimarycentralnervoussystemlymphoma |